US2005054675A1PendingUtilityA1
Interferon $g(g) production promoter
Priority: Nov 2, 2001Filed: Oct 17, 2002Published: Mar 10, 2005
Est. expiryNov 2, 2021(expired)· nominal 20-yr term from priority
A61P 39/06A61P 37/08A61P 43/00A61P 37/02A61P 7/06A61P 37/00A61P 31/12A61P 31/18A61P 31/10A61P 25/00A61P 35/02A61P 35/00A61P 31/22A61P 31/04A61P 31/06A61P 31/00A61P 19/00A61P 17/00A61P 1/02A61P 19/02A61P 1/16C07D 215/12A61K 31/4709C07D 215/10A61P 17/02A61K 31/427C07D 277/30Y02A50/30
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The object of the present invention is to provide an agent for promoting IFN-γ production, which can be safely applied to living bodies; the present invention solves the problem by providing an agent for promoting IFN-γ production, which comprises a tri-heterocyclic polymethine cyanine dye(s), and a method for producing IFN-γ, which comprises a step of allowing the agent to act on immunocompetent cells.
Claims
exact text as granted — not AI-modified1 . An agent for promoting interferon-γ production, which comprises a tri-heterocyclic polymethine cyanine dye.
2 . The agent of claim 1 , wherein said tri-heterocyclic polymethine cyanine dye is represented by the General Formula 1 or 2:
where R 1 , R 2 and R 3 are the same or different aliphatic hydrocarbon groups, and X 1 − is a physiologically acceptable anion;
where R 4 , R 5 and R 6 are the same or different aliphatic hydrocarbon groups, and X 2 − is a physiologically acceptable anion.
3 . The agent of claim 1 , which is used for treating interferon-γ susceptive diseases.
4 . The agent of claim 1 , which is orally administered to living bodies.
5 . A method for producing interferon-γ, which comprises a step of allowing the agent of claim 1 to act on immunocompetent cells.Join the waitlist — get patent alerts
Track US2005054675A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.